bioAffinity Technologies Welcomes New Board Members
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, a privately held cancer diagnostics company, will seat two new members on its Board of Directors at the third-quarter meeting Oct. 26, 2015. Company President and Chief Executive Officer Maria Zannes announced that Myron Holubiak and Barry Frankel are joining the Board.
Holubiak previously served as President of Roche Laboratories, Inc. and now is President and CEO of Leonard-Meron Biosciences, Inc. and Chairman of BioScrip, Inc. He also sits on the Board for Assembly Biosciences, Inc. and is Senior Partner and Director of 1-800-DOCTORS.
Frankel is Managing Director at Huron Consulting Group and serves on the boards of several life science companies. Before he launched the Frankel Group LLC, a leading life science global strategy firm, he held senior positions at Pfizer, Inc.
“The depth and breadth of experience that Myron and Barry bring to our Board will be invaluable as we continue development of our assay for early-stage cancer diagnosis,” said Steve Girgenti, Chairman of the Board. “We have a strong scientific team, and we have the strategic leadership to take the technology to commercialization on a global scale with the potential to positively impact millions of cancer patients.”
Girgenti was founder and CEO of Healthworld, a leading global healthcare marketing firm, and was named NASDAQ’s 1999 Entrepreneur of the Year. Girgenti is a Director of Vycor Medical, Vice Chairman of the Board of Governors for the Mount Sinai Hospital Prostate Disease and Research Center, and sits on the Advisory Board for Vatera Capital.
Holubiak and Frankel join Girgenti, Zannes and Robert A. Anderson on the Board of Directors. Zannes was President of the Energy Recovery Council and managing partner of The Zannes Firm. She is an attorney with more than 30 years of executive-level experience in the medical and energy fields. Anderson has more than 40 years of experience in strategic planning and product launches in the healthcare industry, including senior positions at CIBA, Pfizer, Warner-Lambert-Parke-Davis and Schering Plough.
bioAffinity Technologies’ proprietary technology is based on a porphyrin compound that binds to cancer cells and causes them to fluoresce red under specific frequencies of light. CyPath® Lung, the Company’s first product, is being developed under research collaboration with The University of Texas Health Science Center at San Antonio for the detection of early-stage lung cancer.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151007006258/en/
Maria Zannes, 505-400-9747
Source: bioAffinity Technologies
Released October 7, 2015